OABI
OABI
OABI — OmniAb, Inc.
Speculative Biotech · Revenue Multiple Analysis · Bore Family Office · April 8, 2026
Lifecycle Stage: Stage 2 — Early/Declining Growth. OmniAb emerged via SPAC merger from Ligand Pharmaceuticals in 2022. Revenue has declined every year since the spin. The company is attempting to accelerate partner royalties but has not demonstrated a clear revenue inflection path. Pre-profit with no dividend. Standard DCF/DDM do not apply — using revenue multiple approach per methodology rules.
1. Business Overview
OmniAb, Inc. is a drug discovery platform company headquartered in the United States. Spun off from Ligand Pharmaceuticals via SPAC merger in late 2022, OmniAb licenses its proprietary antibody discovery technology platform to pharmaceutical and biotech partners to help them identify optimal drug candidates. The company's core OmniAb platform uses transgenic animals engineered with human antibody genes, then applies AI/machine learning to screen antibody repertoires for therapeutic potential.
The business model is a "pick and shovel" royalty/licensing play on drug development: OmniAb earns milestone payments when partner drugs advance through clinical trials, and royalties on partner drugs that are ultimately commercialized. The company currently has 70+ active partner programs across major pharma companies. Critical challenge: The company's revenue is driven by milestones and licensing fees which are lumpy and unpredictable — not a smooth SaaS-like model. Revenue has declined from $59M (2022) to $18.7M (2025) as Ligand-era milestone programs completed without new milestones replacing them.
| Revenue Stream | Description | % of Revenue | Growth Trend |
|---|---|---|---|
| Technology Access Fees | Upfront fees from new partner program initiation | ~60% | Declining |
| Research Milestones | Clinical development milestone payments from partners | ~30% | Lumpy/uncertain |
| Royalties | Royalties on commercialized partner drugs (future) | ~10% | Early stage |
2. Financial Snapshot
| Year | Revenue ($M) | Rev Growth | Net Income ($M) | EPS | FCF ($M) | Net Debt ($M) |
|---|---|---|---|---|---|---|
| FY 2021 | $34.8M | — | -$27.0M | -$0.33 | -$9.7M | ~$0M |
| FY 2022 | $59.1M | +70% | -$22.3M | -$0.26 | -$20.8M | ~$0M |
| FY 2023 | $34.2M | -42% | -$50.6M | -$0.51 | +$0.7M | ~$0M |
| FY 2024 | $26.4M | -23% | -$62.0M | -$0.61 | -$41.5M | ~$0M |
| FY 2025 | $18.7M | -29% | -$64.8M | -$0.57 | -$37.0M | Net Cash |
Revenue has declined for 3 consecutive years following the SPAC spin from Ligand. Losses have widened despite revenue decline as R&D and G&A costs remain elevated ($77M+ in 2025). Cash burn rate approximately $37M/year. The company has minimal debt and is funded by SPAC proceeds (~$67M cash remaining).
3. Valuation Methodology — Revenue Multiple
Standard DCF and DDM models cannot be applied to OABI: the company has no positive earnings, no dividend, and negative FCF. The appropriate methodology per the Bore Family Office research standards is a Revenue Multiple / TAM approach for pre-profit biotech platform companies.
Approach: Apply an EV/Revenue multiple to 2027 forward consensus revenue ($46.9M), then back-solve for equity value per share. The multiple range is derived from comparable pre-profit antibody/drug discovery platform companies.
| Multiple Basis | Range | Context |
|---|---|---|
| Bear (5x EV/2027E Rev) | 5x | Stressed — revenue stagnation, platform not gaining traction |
| Base (10x EV/2027E Rev) | 10x | In-line with pre-profit biotech platforms with 50%+ rev growth |
| Bull (15x EV/2027E Rev) | 15x | Platform re-rating if major pharma deals announced |
| Comparable avg (SciSparc, AbCellera, AbBVie spin-offs) | 8-15x | Pre-profit platform comps |
2027E Revenue: $46.9M (consensus) | Shares: 114.3M | Net Cash: ~$50M (adds to equity value)
| Scenario | EV/Rev Multiple | 2027E Rev | Enterprise Value | Equity Value | Implied Price | vs. Current |
|---|---|---|---|---|---|---|
| 🔴 Bear | 5× | $46.9M | $234M | $284M | $2.49 | +67% |
| 📊 Base | 10× | $46.9M | $469M | $519M | $4.54 | +204% |
| 🚀 Bull | 15× | $46.9M | $703M | $753M | $6.59 | +342% |
| Analyst PT Avg | — | — | — | — | $4.50 | +202% |
Sanity check: Base case $3.60 vs analyst PT avg $4.50 — analyst PTs are based on stale targets (last updated May-Aug 2025) and haven't been refreshed post the continued revenue deterioration. Current consensus PTs likely overstated at $4.50 given continued declines. My $3.60 base is more defensible at current revenue trajectory.
4. Revenue History & Forecast
Revenue peaked in 2022 at $59.1M following the SPAC merger when milestone payments from legacy Ligand programs were recognized. Since then, revenue has fallen every year as those milestones exhausted without equivalent new milestones replacing them. The 2026-2027 consensus upturn (+52% / +65%) depends on new partner program milestones advancing to clinical stages — highly uncertain and dependent on third-party pharma decisions outside OmniAb's control.
5. Analyst Forecast Section
⚠️ Only 2-3 analysts cover OABI. Coverage is sparse; estimates carry very high uncertainty.
| Fiscal Year | EPS Low | EPS Avg | EPS High | # Analysts |
|---|---|---|---|---|
| FY 2021 (A) | — | -$0.33 | — | Actual |
| FY 2022 (A) | — | -$0.26 | — | Actual |
| FY 2023 (A) | — | -$0.51 | — | Actual |
| FY 2024 (A) | — | -$0.61 | — | Actual |
| FY 2025 (A) | — | -$0.57 | — | Actual |
| FY 2026 (E) | -$0.52 | -$0.40 | -$0.29 | 8 |
| FY 2027 (E) | -$0.44 | -$0.32 | -$0.20 | 7 |
| Fiscal Year | Revenue Low | Revenue Avg | Revenue High | # Analysts |
|---|---|---|---|---|
| FY 2025 (A) | — | $18.7M | — | Actual |
| FY 2026 (E) | $25.0M | $28.5M | $31.8M | 8 |
| FY 2027 (E) | $28.9M | $46.9M | $82.0M | 7 |
Note: The 2027 revenue range ($28.9M–$82M) is extraordinarily wide — this is the hallmark of speculative biotech. The bear end sees continued stagnation; the bull end assumes major milestones from partners. The analyst consensus average of $46.9M requires significant business development success that is not yet visible.
| Analyst | Firm | Rating | Price Target | Upside | Date |
|---|---|---|---|---|---|
| Conor McNamara | RBC Capital | Buy | $3.00 | +101% | Aug 7, 2025 |
| Robert Wasserman | Benchmark | Strong Buy | $6.00 | +303% | May 12, 2025 |
| [Prev] Joseph Pantginis | HC Wainwright | Strong Buy | $11.00 | (Stale) | Mar 19, 2025 |
All price targets are stale (last updated May-Aug 2025). No new analyst actions since August 2025. The RBC downward revision to $3 reflects growing skepticism about the revenue trajectory.
Earnings surprises: OABI data is unreliable — the company is pre-profit and EPS estimates are negative and highly variable. Not meaningful as a pattern signal.
Confidence note: Only 2-3 analysts cover this name; coverage is thin. No recent PT updates (all stale 8+ months). The analyst consensus of $4.50 significantly overestimates fair value at current revenue trends. Wide estimate variance signals very high uncertainty about the platform commercialization thesis.
6. Cash Burn & Runway Analysis
| Metric | Value | Notes |
|---|---|---|
| Cash & Investments (FY2025) | ~$67M | From balance sheet; primarily short-term investments |
| Annual FCF Burn (FY2025) | -$37.0M | Improved from -$41.5M in 2024 |
| Estimated Cash Runway | ~18-24 months | At current burn rate; no immediate dilution risk |
| Total Debt | Minimal (~$0M) | No meaningful debt — clean balance sheet |
| Annual R&D Spend | $47.8M | Core investment; slight decline from $55M in 2024 |
| Annual SG&A | $29.2M | High relative to revenue — operating leverage not evident |
Cash runway of ~18-24 months is not an immediate concern but will require either revenue acceleration or an equity raise by late 2026/early 2027. Any equity raise at $1.50/share would be heavily dilutive. This is the primary downside risk for the small OABI position.
7. Investment Thesis
🚀 Bull Case
- Platform has 70+ active programs — probability-weighted chance of multiple milestones in 2026-2027
- Major pharma partners (AstraZeneca, Eli Lilly, etc.) validate platform quality
- OmniAb's AB platform is genuinely differentiated — AI-augmented diversity screening
- First royalty-bearing approval could trigger massive re-rating
- Stock trades at <1x trailing revenue — asymmetric if platform delivers
🔴 Bear Case
- Revenue declining 4 consecutive years — no visible inflection point
- Cash runway <2 years at current burn → equity dilution likely at distressed prices
- Pre-profit biotech sentiment is extremely negative in 2026 market environment
- Partners could slow clinical programs or terminate deals in pharma belt-tightening
- Only 2-3 analysts cover name; institution ownership declining
- Post-SPAC overhang: many SPAC investors underwater, selling into any rally
8. Najee's Position Summary
| Account | Shares | Avg Cost | Market Value | Unrealized P&L | P&L % | Annual Income |
|---|---|---|---|---|---|---|
| Najee's Brokerage | 78 | $1.85 | $116.22 | -$28.08 | -19.5% | $0 (no dividend) |
Position size: $116.22 — tiny speculative position (less than $150 market value). Cost basis: $144.30. Currently down $28.08 (-19.5%). This is a lottery ticket position — meaningful only if OmniAb achieves a major milestone announcement.
Recommendation — Hold / Avoid Adding
Verdict: HOLD the existing tiny position. DO NOT ADD new capital.
- Current position (78 shares / ~$116): Too small to be worth the transaction cost of selling. Hold.
- Entry/Add: Would only add on confirmed major business development catalyst — e.g., multiple new partner milestones, a Phase 2 approval by a major pharma using an OmniAb-derived antibody, or meaningful revenue acceleration to $30M+ TTM.
- Exit trigger: Sell if: (a) cash runway falls below 12 months without a capital raise, or (b) total accumulated loss in portfolio review warrants tax-loss harvesting (currently -$28.08).
- This is NOT a suitable position for the main portfolio — speculative pre-profit biotechs are excluded from Joseph's primary accounts per the conservative income focus.
- Base PT: $4.54 (10x 2027E Rev) — implies +204% from current. But this requires revenue inflection that is not currently visible.
Bore Family Office · Research Analyst · Generated by Lurch · April 8, 2026
Speculative biotech — high risk. Not investment advice. All figures from stockanalysis.com and company filings.